Valneva outlines ???170M-???180M sales target for 2025 with focus on IXCHIQ and Lyme vaccine developments

Earnings Call Insights: Valneva SE (VALN) Q4 2024

Management View

• CEO Thomas Lingelbach highlighted that Valneva achieved double-digit year-on-year sales growth, with total product sales surpassing ???160 million for 2024, in line with guidance. The company ended the year with a cash position near ???170